Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277966 | 1.00 | PPM1D (0.33) | PPM1D | |
| SCHEMBL277967 | 1.00 | PPM1D (0.33) | PPM1D | |
| SCHEMBL1896226 | 0.92 | PPM1D (0.35) | PPM1D | |
| SCHEMBL16516673 | 0.89 | PPM1D (0.33) | PPM1D | |
| SCHEMBL1015667 | 0.88 | PPM1D (0.34) | PPM1D | |
| SCHEMBL20758481 | 0.88 | PPM1D (0.34) | PPM1D | |
| SCHEMBL18535817 | 0.88 | PPM1D (0.34) | PPM1D | |
| SCHEMBL5831542 | 0.88 | PPM1D (0.34) | PPM1D | |
| SCHEMBL360950 | 0.88 | PPM1D (0.36) | PPM1D | |
| SCHEMBL661089 | 0.88 | PPM1D (0.34) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054493-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| WO-2023143135-A1 | QUINAZOLINE DERIVATIVE AND USE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2023-08-03 | — | — | WO | disclosed |
| EP-3426245-B1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-109069488-B | Hepatitis B antiviral agent | 英安塔制药有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-20210230176-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-07-29 | — | — | US | disclosed |
| US-10934306-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200199143-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2020-06-25 | — | — | US | disclosed |
| US-20190084994-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2019-03-21 | — | — | US | disclosed |
| EP-3426245-A1 | HEPATITIS B ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| US-10179133-B2 | Pyrrolopyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-01-15 | — | — | US | disclosed |
| EP-2344494-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2229396-A1 | SPIROINDOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| WO-2010027500-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010027500-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009077357-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084994-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | PPM1D 2079/4885 |
| US-20210230176-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | PPM1D 2079/4885 |
| US-20090156610-A1 | Spiroindolinone Derivatives | SDHA, AR, XPOT | PPM1D 2462/4885 |
| US-12054493-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | PPM1D 2079/4885 |
| US-20200199143-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | PPM1D 2079/4885 |
| US-10934306-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | PPM1D 2079/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | PPM1D 992/4885 |
| US-10179133-B2 | Pyrrolopyrimidine compounds for the treatment of cancer | XDH, DPYD, TPX2 | PPM1D 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.